BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Acucela Inc. 

1301 Second Avenue
Suite 1900, 19th Floor
Seattle  Washington  98101-3805  U.S.A.
Phone: 206-805-8300 Fax: 206-805-8301


SEARCH JOBS


Acucela Inc. is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for treating blinding eye diseases that affect tens of millions of people worldwide. The company’s orally-delivered VCM therapies, which selectively target cells within the retina to protect visual acuity, have the potential to be used to treat several devastating eye diseases, including dry age-related macular degeneration (AMD), retinopathy of prematurity, Stargardt disease and diabetic retinopathy. Acucela is also developing, with Otsuka Pharmaceutical, Rebamipide ophthalmic suspension, a Phase 3 product candidate for dry eye.

For more information, please visit www.Acucela.com.


 Key Statistics


Email: investor@acucela.com
Ownership: Private

Web Site: Acucela
Employees:
Symbol: 
 



Industry
Biotechnology






 Company News
Acucela Provides Important Company Updates 4/27/2015 11:26:15 AM
Acucela Granted New Patent Covering Method Of Use For Emixustat Hydrochloride 4/1/2015 12:33:02 PM
Washington State Court Issues Order Requiring Acucela To Hold Special Shareholders Meeting 3/16/2015 1:02:35 PM
Proxy Fight Looms as Acucela Snaps Back at Ousted CEO 3/13/2015 6:06:57 AM
Acucela Files Opposition To SBI/Kubota Motion To Compel Company To Call Special Shareholders Meeting 3/12/2015 10:21:17 AM
Ousted Acucela CEO Continues to Fight Over Board Members and the Biotech's Future 3/10/2015 6:10:03 AM
Acucela Inc. To Hold 2015 Annual Meeting Of Shareholders On June 8, 2015 3/4/2015 11:24:26 AM
Acucela Inc. Received A Request To Hold A Special Meeting Of Shareholders 2/3/2015 12:57:05 PM
Large Acucela Inc. Shareholder Wants to Oust Four Out of Five Board Members 2/3/2015 6:50:48 AM
Acucela Inc. Announces That Brian O’Callaghan Will Assume The Role Of CEO; Ryo Kubota, M.D., Ph.D., To Remain Chairman Of The Board 12/23/2014 8:29:56 AM
1234567